Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Cagrilintide for Sale > Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3
Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3 buy - large image1
Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3 buy - image1
Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3 buy - image2
Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3 buy - image3
Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3 buy - image4
Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3 buy - image5
Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3 buy - image6

Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3

TDS 61 Inquiries

Unit Price:

$87/UNIT FOB

Get Latest Price
CAS No.:

1415456-99-3

Grade:

Laboratory Grade

Content:

99%

Port:

guangzhou

Brand:

Novio

Packaging:

5mg*10vials

Price valid (until):

2026-09-30

Company Type:
Trader
Location:
China
Qualification:
Main Products:

Peptides,Cosmetic Raw Materials,Pharmaceutical Intermediates

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Cagrilintide (1415456-99-3) | High-Purity GLP-1R/AmyR Dual Agonist Peptide for Obesity & T2DM Research

    Product Overview
    Cagrilintide, with research codes AM833, NN9838, and ZP8396, is a long-acting acylated amylin analog developed by Novo Nordisk. As a dual agonist peptide targeting both the GLP-1 receptor and the amylin receptor (AmyR), it is currently undergoing Phase III clinical trials (ECHEMI) globally for obesity and type 2 diabetes. Unlike traditional single-target GLP-1 drugs (such as smegglutide) and dual-target GLP-1/GLP-1 drugs (such as telpolide), Cagrilintide achieves more significant weight loss and glycemic control through the synergistic action of the GLP-1 and amylin pathways, making it a breakthrough compound (PMC) in the field of metabolic disease research.
    Shop Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3-Detailed Image 1 Shop Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3-Detailed Image 2 Shop Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3-Detailed Image 3 Shop Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3-Detailed Image 4 Shop Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3-Detailed Image 5



    Our Cagrilintide is synthesized using advanced solid-phase peptide synthesis (SPPS) technology, followed by high-resolution purification and lyophilization to ensure maximum stability and biological activity. Each batch is accompanied by a comprehensive Certificate of Analysis (COA) confirming compliance with all specificationsECHEMI

    Mechanism of Action: Dual Pathway Synergy


    Cagrilintide exerts its effects through two complementary hormonal pathways, delivering superior metabolic benefits compared to single-target agents:

    1. GLP-1 Receptor Activation


    • Enhances glucose-dependent insulin secretion
    • Suppresses glucagon release, reducing hepatic glucose production
    • Promotes satiety and reduces food intake
    • Slows gastric emptying to improve postprandial glycemic control

    2. Amylin Receptor (AmyR) Stimulation


    • Potently delays gastric emptying (more pronounced than GLP-1 alone)
    • Inhibits appetite through central nervous system pathways
    • Reduces body weight by enhancing energy expenditure
    • Modulates postprandial glucose fluctuations independently of GLP-1 pathwayECHEMI

    Synergistic Advantage: The dual-action mechanism addresses metabolic dysfunction through multiple pathways, overcoming the compensatory responses that limit the efficacy of single-target therapies. Clinical data from the REDEFINE 1 Phase III trial demonstrated that the combination of Cagrilintide with semaglutide (CagriSema) achieved 20.4% mean weight loss—significantly exceeding results from GLP-1 monotherapy.

    Items Specifications
    purity ≥99.0%(HPLC)
    Molecular formula C₁₉₄H₃₁₂N₅₄O₅₉S₂
    CAS NO 1415456-99-3

    ⚠️ Critical Note: This product is for research use only and not for human or animal clinical use. It is strictly intended for laboratory research applications only.
    Shop Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3-Detailed Image 6 Shop Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3-Detailed Image 7 Shop Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3-Detailed Image 8 Shop Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3-Detailed Image 9


    Research Applications


    Cagrilintide is an invaluable tool for researchers investigating metabolic diseases, obesity, and diabetes. Key applications include:

    1. Obesity Research


    • Studying central and peripheral satiety signaling pathways
    • Evaluating synergistic weight loss mechanisms with GLP-1 agonists
    • Developing novel combination therapies for treatment-resistant obesity

    2. Type 2 Diabetes Mellitus (T2DM)


    • Investigating glucose-lowering effects beyond insulin secretion
    • Exploring postprandial glycemic control mechanisms
    • Evaluating beta-cell protection and regeneration potential

    3. Metabolic Syndrome


    • Researching the role of amylin in lipid metabolism and cardiovascular risk
    • Developing polypharmacy approaches for comprehensive metabolic regulationPMC

    4. Drug Discovery


    • Serving as a reference standard for novel GLP-1/AmyR dual agonists
    • Validating amylin receptor as a therapeutic target
    • Optimizing peptide modification strategies for enhanced pharmacokinetics

    Storage & Stability Guidelines


    To maintain optimal activity and stability of Cagrilintide:

    Powder Form Storage


    • Long-term storage: -20°C to -80°C, sealed, protected from light and moisture, under nitrogen atmosphere (3-year shelf life)ECHEMI
    • Short-term storage: 2-8°C, sealed, protected from light (1-2 years shelf life)
    • Avoid: Repeated freeze-thaw cycles, exposure to extreme temperatures, or prolonged ambient conditions

    • Safety Information & Handling


      Laboratory Safety Precautions


      • Wear appropriate PPE: gloves, lab coat, safety glasses
      • Use in a well-ventilated fume hood
      • Avoid inhalation, ingestion, or contact with skin and eyes
      • Dispose of waste material in accordance with local regulations for peptide compounds

      Potential Biological Effects


      • May cause gastrointestinal reactions (nausea, vomiting, bloating) in animal models—similar to GLP-1 class agents
      • Handle with care as it exhibits potent biological activity at low concentrations
      • Not for human or animal therapeutic use—strictly for research purposes only

    Why Choose Our ?


    1. Ultra-High Purity (≥99.0%): Ensures minimal interference in research results
    2. Structural Integrity: Preserves the critical Cys3-Cys8 disulfide bridge and N-terminal modification
    3. Comprehensive Documentation: COA with full analytical data provided for every batch
    4. Stability Guaranteed: Rigorous quality control ensures consistent performance
    5. Research Expertise: Technical support from experienced peptide scientists
    6. Global Shipping: Reliable delivery to research institutions worldwide

    Ordering Information


    To place an order or request a sample, please contact our sales team:

    Shop Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3-Detailed Image 10

    ECHEMI Editorial Reference

    Cagrilintide is a long-acting amylin analog and peptide-based pharmaceutical ingredient. As a pharmaceutical raw material, Cagrilintide is characterized by its peptide structure and amylin receptor activity. It is suitable for API research, analytical testing, pharmaceutical development, and related manufacturing processes.

    Certificates
    • Carglinide, a long-acting amylin analogue, 99% pure, research peptide, CAS 1415456-99-3 Certificates 1 TDS

    Basic Info
    Product Name:

    Cagrilintide

    Other Name:

    Cagrilintide;Cargliptin;Caglitide;Cagrilintide acetate;Cagrilintide peptide;Cagrilintide 5mg 10mg 15mg;Cagrilintide(Acetate form);Kagliptin

    CAS No.:

    1415456-99-3

    Molecular Weight:

    0

    EC Number:

    206-141-6

    Color/Form:

    White to off-white

    Research
    Class:

    Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)

    Status:

    Investigational — Phase 3 (REDEFINE program, CagriSema combination)

    Mechanism:

    A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity. Administered once weekly.

    Activity note:

    Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.

    Source:

    MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.

    Clinical Development:

    NCT05249895; NCT05249882

    References
    PubChem:

    PubChem

    Disclaimer:

    Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Peptides,Cosmetic Raw Materials,Pharmaceutical Intermediates

    Location:

    Room 1359, Room 103, Building Jia 19, Jixiang Garden, Tongzhou District, Beijing

    Year of Establishment:

    2026

  • Inquiry History
    61 Inquiries
    Country Product Purchase Quantity Date Posted
    Australia

    Cagrilintide

    20 MG Aug 17, 2026
    United Kingdom

    Cagrilintide

    10 MG Jul 31, 2026
    France

    Cagrilintide

    10 MG May 22, 2026
    Australia

    Cagrilintide

    4 MT Mar 9, 2026
    United States

    Cagrilintide

    15 MG Feb 25, 2026
    United States

    Cagrilintide

    10 PCS Dec 27, 2025
    United States

    Cagrilintide

    2 MT Dec 21, 2025
    United States

    Cagrilintide

    100 MG Oct 28, 2025
    United States

    cagrilintide

    2 MT Aug 8, 2025
    Philippines

    Retatrutide

    5 MG Aug 5, 2025
    China

    Cagrilintide

    100 G May 6, 2025
    United States

    cagrilintide

    5 MG Feb 18, 2025
    United States

    Cagrilintide

    3 MT Feb 7, 2025
    United States

    Cagrilintide

    100  Nov 12, 2024
    United States

    Cagrillintide Lyophilized powder

    100 MG Jul 4, 2024
    United States

    Cagrillintide Lyophilized powder

    1000 MG Apr 20, 2024
    United States

    Cagrlintide

    1 MT Jul 31, 2026
    United Kingdom

    cagrilintrude

    20 MG Jul 21, 2026
    United States

    Cagrilintide

    1 KG Jul 17, 2026
    United States

    Cagrilintide

    30 MG May 26, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.